21 Nov 2018 13:00
SalvaRx Group plc
("SalvaRx", the "Company" or the "Group")
Transaction Update
Further to the announcements of 14 and 28 August 2018 relating to the proposed disposal of the Company's 94.2% interest in SalvaRx Limited to Portage Biotech Inc. ("Portage"), the Company is pleased to announce that the Portage shareholder meeting to approve the transaction has been set for 8 January 2019 and meeting materials will be sent to Portage shareholders on the Portage record date, being 23 November 2018. Trading in Portage shares on the Canadian Securities Exchange is expected to resume shortly after the meeting materials have been posted.
The Company will now finalise and publish its shareholder circular and a further announcement will be made by the Company in due course.
Enquiries
SalvaRx Group plc |
| |
Ian Walters (Chief Executive) | Tel: +1 203-441-5451 | |
Northland Capital Partners Limited Nominated Adviser and Broker | Tel: +44 (0) 20 3861 6625
| |
Matthew Johnson / Edward Hutton (Corporate Finance) | ||
Vadim Alexandre (Corporate Broking) | ||
Peterhouse Capital Limited Joint Broker Lucy Williams / Duncan Vasey | Tel: +44 (0) 20 7469 0932 | |